ReviewDiabetes care2026
8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026.
Review in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- The Effect of Integrated Lifestyle Intervention Incorporating Calorie-Carbohydrate Restriction With or Without Time-Restricted Feeding for Remission of Type 2 Diabetes (DIREM): A Single Blind Randomised Controlled Trial.Endocrinology, diabetes & metabolism · 2026Trial
- GLP-1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation.Diabetes, obesity & metabolism · 2026Article
- Prevalence of overweight and obesity and associated factors among persons with type 2 diabetes mellitus in Ethiopia: A systematic review and meta-analysis.Obesity pillars · 2026Review
- Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.Diabetes, obesity & metabolism · 2026Review
- Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice.Endocrinology, diabetes & metabolism · 2026Observational
- Persistence in GLP-1-Based Therapy Among Adults with Obesity and Type 2 Diabetes: A Narrative Review of Definitions, Real-World Outcomes, and Determinants.Current diabetes reports · 2026Review
- Sugar Shockwaves: How the Fructose-Glucose-ChREBP Pathway Hijacks Liver Metabolism.Life (Basel, Switzerland) · 2026Review
- Achieving at Least 15% Weight Loss Within 2 Years of Type 2 Diabetes Diagnosis Is Associated With Lower Risks of Macrovascular and Microvascular Complications: A U.K. Cohort Study.Diabetes care · 2026Article
- Myoprotective Fat-Loss Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study of Metformin-Based Treatment Regimens.Clinics and practice · 2026Article
- Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- A combined model integrating adiponectin and anthropometric indices for the identification of insulin resistance in patients with type 2 diabetes mellitus.BMC endocrine disorders · 2026Article
- Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making.EClinicalMedicine · 2026Review
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.Metabolism open · 2026Review
- Predictors of Postoperative Complications in Metabolic and Bariatric Surgery: A Retrospective Analysis Using Multivariable Logistic Regression.Medicina (Kaunas, Lithuania) · 2026Article
- Review
- Merging T1D and T2D Management: Shared Strategies for Common Goals-Building on Early Lessons From GLP-1 Trials in T1D.Diabetes care · 2026Article
- Impact of a Clinical Pharmacist on Weight Loss Outcomes in Primary Care Patients Without Diabetes.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2026Article
- Prevalence of Therapeutic Inertia in the Management of Overweight and Obesity in Patients With a Diagnosis of Type 2 Diabetes Who Are Followed up by Primary Care Physicians.Obesity science & practice · 2026Article
- Bridging the Care Gap: Family Support for Adults Living with Diabetes Mellitus in Limpopo Province, South Africa.International journal of environmental research and public health · 2026Article
- Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity.BMJ open diabetes research & care · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee for Diabetes, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.